Appointed
Martin H. Huber
Class III Director
ACTU ·
ACTUATE THERAPEUTICS, INC.
appointed Martin H. Huber, MD, to the Board.
leadership
confidence high
sentiment positive
materiality 0.50
Actuate Therapeutics appoints former Mersana CEO Martin Huber to board
ACTUATE THERAPEUTICS, INC.
- Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.
- Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.
- Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.
- He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.
- Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer.
item 5.02item 8.01item 9.01
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.